Elevated reactive oxygen species can drive the alternative lengthening of telomeres pathway in ATRX-null cancers.

in Nucleic acids research by Tomas Goncalves, Siobhan Cunniffe, Tiffany S Ma, Natalie Mattis, Andrew W Rose, Thomas Kent, David R Mole, Helene E B Geiller, Linda van Bijsterveldt, Timothy C Humphrey, Ester M Hammond, Richard J Gibbons, David Clynes, Anna M Rose

TLDR

  • Researchers identify excessive reactive oxygen species (ROS) as a key driver of the ALT pathway in cancer cells, highlighting potential therapeutic targets to prevent ALT pathway activity and treat ALT-positive cancers.

Abstract

The alternative lengthening of telomeres (ALT) pathway is a telomerase-independent mechanism for immortalization in cancer cells and is commonly activated in low-grade and high-grade glioma, as well as osteosarcoma. The ALT pathway can be activated under various conditions and has often been shown to include mutational loss of ATRX. However, this is insufficient in isolation and so other cellular event must also be implicated. It has been shown that excessive accumulation of DNA:RNA hybrid structures (R-loops) and/or formation of DNA-protein crosslinks (DPCs) can be other important driving factors. The underlying cellular events leading to R-loop and DPC formation in ALT cancer cells to date remain unclear. Here, we demonstrate that excessive cellular reactive oxygen species (ROS) is an important causative factor in the evolution of ALT-telomere maintenance in ATRX-deficient glioma. We identified three sources of elevated ROS in ALT-positive gliomas: co-mutation of SETD2, downregulation of DRG2, and hypoxic tumour microenvironment. We demonstrate that elevated ROS leads to accumulation of R-loops and, crucially, resolution of R-loops by the enzyme RNase H1 prevents ALT pathway activity in cells exposed to elevated ROS. Further, we found a possible causal link between the formation of R-loops and the accumulation of DPCs, in particular, formation of TOP1 complexes covalently linked to DNA (Top1cc). We also demonstrate that elevation of ROS can trigger over-activity of the ALT pathway in osteosarcoma and glioma cell lines, resulting in excessive DNA damage and cell death. This work presents important mechanistic insights into the endogenous origin of excessive R-loops and DPCs in ALT-positive cancers, as well as highlighting potential novel therapeutic approaches in these difficult-to-treat cancer types.

Overview

  • The study explores the alternative lengthening of telomeres (ALT) pathway in cancer cells, focusing on its activation in low-grade and high-grade glioma, osteosarcoma, and other cancer types.
  • The researchers investigate the underlying cellular events leading to DNA:RNA hybrid structures (R-loops) and DNA-protein crosslinks (DPCs) formation in ALT cancer cells.
  • The primary objective is to identify novel therapeutic approaches by understanding the mechanisms driving excessive R-loops and DPCs formation in ALT-positive cancers.

Comparative Analysis & Findings

  • The study identifies three sources of elevated reactive oxygen species (ROS) in ALT-positive gliomas: co-mutation of SETD2, downregulation of DRG2, and hypoxic tumour microenvironment.
  • Elevated ROS leads to accumulation of R-loops, which can be resolved by the enzyme RNase H1, thereby preventing ALT pathway activity.
  • The researchers found a possible causal link between R-loops and DPCs, particularly the formation of TOP1 complexes covalently linked to DNA (Top1cc).

Implications and Future Directions

  • The study highlights the potential for targeting ROS accumulation as a therapeutic strategy for preventing ALT pathway activity and treating ALT-positive cancers.
  • Further research is needed to investigate the specific roles of SETD2, DRG2, and hypoxia in promoting ALT pathway activity in cancer cells.
  • The findings suggest that targeting R-loop resolution enzymes, such as RNase H1, could also be a promising therapeutic approach in ALT-positive cancers.